Hereditary Angioedema Market to be at Forefront by 2025

Posted by Jack Martin on February 8th, 2018

Flow of blood or lymphatic fluid, continuous accumulation of fluids outside of the blood vessels, results in swelling of tissues in the arms, feet, intestinal tract, face, or airway. Stress or Minor trauma may also trigger an attack, Swelling in the airway can limit breathing and prompt to life-debilitating obstruction of the airway. Around 33% of individuals with this condition faces non-itchy rash called erythema marginatum at the time of an attack. risk of passing the abnormal gene to offspring from affected parent is half (50%) for every pregnancy regardless of the sex of the subsequent child.

Hereditary angioedema (HAE) is inherited as an autosomal dominant trait, because of a malfunction or lack of C1 esterase inhibitor. Hereditary angioedema (HAE) classified into three types:  gene While Type III HAE is due to the mutation in F12 gene. According to NIH Organization, Hereditary angioedema is evaluated to affect 1 in 50,000 individuals. Type I is major, representing 85% of cases followed by Type II which occurs in 15% of cases, and Type III is extremely rare. This is expected to reflect positive growth in the global Hereditary Angioedema market.

The Hereditary Angioedema Association has assumed a pivotal part in conveying new therapies to the market. They have additionally attempted to increase awareness about products and support services that HAE patients require, this is relied upon to reflect positive development in Hereditary Angioedema market. Increase in a population with the change in lifestyle, Improvement in reimbursement infrastructures and Increase in efforts of pharmaceutical manufacturers and biotechnology companies to come up with new solutions and products to the market which expected to fuel the market revenue for Hereditary Angioedema over the forecast period. However, high expenses of medicines, misdiagnosis of the disorder are few of the factors that can restrain the growth of the Hereditary Angioedema market during the forecast period.

Hereditary Angioedema may be acquired or inherited; it is predominant in children. Major players in this segment are taking an advanced approach to constructing prevalent products as well as to expand their potential revenues which will lead to increase in the global Hereditary Angioedema market through 2025. Shire plc Recognizes HAE Day(16 May) with Launch of Interactive Website Calling for Inspirational Wishes intends to raise awareness among the overall population, show support and ensure better care with a more accurate diagnosis for those who are challenged with this condition. The increase in awareness, improved management, and better outcomes are the factors that drive the Hereditary Angioedema market that is expected to have a meteoric growth over a forecast period.

A geographic condition regarding for Hereditary Angioedema market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa. Majorly North America and Europe dominates the global Hereditary Angioedema market followed by Asia- Pacific. Chang in lifestyle and continuous efforts in the management of healthcare services demonstrates the elevation of the Hereditary Angioedema market.

Request to View Sample of Research Report @ 

Major market players of hereditary angioedema market constitute: BioCryst Pharmaceuticals, Inc, CSL Limited, Pharming Group NV, Salix Pharmaceuticals, Shire plc.

Like it? Share it!

Jack Martin

About the Author

Jack Martin
Joined: August 7th, 2017
Articles Posted: 1,325

More by this author